Oriahnn Kit
Product Images NDC 0074-1017

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oriahnn (NDC 0074-1017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oriahnn Spl 01

A line graph showing mean percent change from baseline with 95% confidence intervals over 12 months of treatment and off-treatment periods for Oriahnn and placebo groups. The x-axis shows time points (Month 0, 6, 12) and the study phases (on treatment, off treatment). The y-axis displays mean percent change values ranging from -3% to 1%. The graph compares Oriahnn and placebo responses over time with sample sizes indicated for each time point.*

FDA Label Image

Oriahnn Spl 02

Chemical structure diagram of the active ingredient Elagolix, as indicated by the arrangement of rings, functional groups, and atoms shown in the molecular formula.*

FDA Label Image

Oriahnn Spl 03

Chemical structure of Estradiol, one of the active ingredients in the drug kit Oriahnn. The diagram shows the molecular structure including hydroxyl groups and stereochemistry.*

FDA Label Image

Oriahnn Spl 04

Chemical structure of Elagolix, one of the active ingredients in Oriahnn. The diagram shows a steroidal backbone with specific stereochemistry, including acetyl and ketone functional groups, characteristic of the Elagolix molecule.*

FDA Label Image

Oriahnn Spl 05

Line graph showing least squares mean change with 95% confidence intervals from baseline over 6 months for two groups: Placebo and ORIAHNN. The x-axis represents time points from baseline to month 6, and the y-axis measures the change from baseline. ORIAHNN shows a marked decrease over time, while placebo remains near baseline levels.*

FDA Label Image

Oriahnn Spl 06

A line graph comparing least squares mean changes from baseline over six months between Placebo and ORIAHNN in subjects. The y-axis shows LS mean change (95% CI) from baseline ranging from -300 to 100, while the x-axis represents time from baseline through month 6. The ORIAHNN group shows a significant decline early, stabilizing below -150, whereas the Placebo group remains near zero. Subject numbers for each group are listed below the x-axis at each time point.*

FDA Label Image

Oriahnn Spl 07

Packaging label for Oriahnn kit containing capsules. The label shows the product name Oriahnn with active ingredients Elagolix, Estradiol, and Norethisterone, including strength details in milligrams. The kit is labeled for prescription use, includes several capsule counts per section, and is manufactured by AbbVie Inc. The layout includes UPC barcode and labeling information on a white background with teal graphical design.*

FDA Label Image

Oriahnn Spl 08

Packaging label for Oriahnn kit containing Elagolix and Estradiol and Norethisterone capsules. The label states a total of 14 capsules for 7 days co-packaged for oral use. The label features the AbbVie Inc. labeler information and includes a colorful floral logo on a white background with dosing instructions and regulatory text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.